Spark Biomedical, developer of the Sparrow ™ Therapy System — a discrete, wearable, over-the-ear, medical device designed for opioid withdrawal relief — announces the official formation of the company’s Medical Advisory Board on Pain Management.
While instances of Neonatal Opioid Withdrawal Syndrome (NOWS) are still on the rise, and the eyes of the nation remain focused on a pandemic, the Medical University of South Carolina (MUSC) and Spark Biomedical, Inc. are tackling opioid withdrawal in newborns — the most innocent victims of the still-looming opioid crisis. This groundbreaking clinical trial pairs Spark’s Transcutaneous Auricular Neurostimulation (tAN™) device for newborns — the Roo — with the pediatric neurostimulation expertise and facilities of MUSC to develop a safe and more effective withdrawal relief solution for NOWS.
The highlight of the 2020 NANS session was a competition among 12 new and emerging firms in the neuromodulation industry. Each entrepreneur was give 10 minutes to present and then field questions from the judges and the audience in an effort to win cash prizes and “Best in Show.”
